FEN-1 Antibody (4E7) - Azide and BSA Free

Western Blot: FEN-1 Antibody (4E7) - Azide and BSA Free [NB100-150] -

miR-1193 directly targets YY1AP1 and exhibits synthetic lethality with DNA-PKcs through the YY1-FEN1 pathway.a Predicted miR-1193 binding sequence in the 3′-UTR of YY1AP1 (wild-type YY1AP1-3′-UTR) and in a mutant containing seven altered nucleotides indicated in red (YY1AP1-3′-UTR-mut). b Luciferase activity of the reporter constructs containing the 3′UTR of YY1AP1 with the wild-type or mutated miR-1193 binding site in 293 T cells after co-transfection with the control or miR-1193 expression constructs. The mRNA levels of miR-1193 (c) and YY1AP1 (d) were measured by RT-qPCR in M059K or M059J cells transfected with anti-miR-NC or anti-miR-1193. U6 RNA was used as the internal control. e Protein expression levels of YY1AP1, YY1, and FEN1 in M059K and M059J cells transfected with anti-miR-NC or anti-miR-1193. GAPDH was used as the loading control. f Colony formation assay of M059K and M059J cells transfected with shNC and shFEN1 and cultured for 4 days. The expression levels of FEN1 and GAPDH are presented. g The viability of transfected M059K and M059J cells was measured with a CCK8 kit across a time course. h Cell proliferation was measured by an EdU analysis of FACS. i Apoptosis was measured by a TUNEL assay and quantified. j, k The percentage of cells in S-phase and apoptosis under each condition was quantified. The images are representative of three independent biological replicates. The data are presented as the mean +/- SD values, and the error bars represent data from triplicate biological experiments. *P < 0.05, **P < 0.01, ***P < 0.005. NS not significant: p > 0.05. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/32732911), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: FEN-1 Antibody (4E7) - Azide and BSA Free [NB100-150] -

FEN1 Deficiency Resulted in Failure of RAD51-BRCA1 Assemble and Increased Fork Degradation. a Expression of FEN1, BRCA1 and RAD51 in glioma mice sample with or without FEN1 specific inhibitor sc-13 treatment. b Quantitation of FEN1, BRCA1 and RAD51 level. c, Correlation between FEN1 and BRCA1 protein expression in TCGA database. d Correlation between FEN1 and RAD51 protein expression in TCGA database. e M059K cells were transfected with control (siNC) or FEN1 siRNA (siFEN1) for 48 h followed with 2 mM HU treatment for 4 h. Immunofluorescence labeling was performed to detect foci of BRCA1 and RAD51. Quantitation of BRCA1 and RAD51 was presented from three independent replicates. Data are mean +/- s.d. f Detection of BRCA1-RAD51 interaction was carried out by PLA labeling in M059K cells transfected with siNC or siFEN1 followed with 2 mM HU for 4 h. Representative images are shown. Scale bars, 5 μm. The scatterplot displays quantification of the PLA signals per nucleus from at least 100 cells from three independent experiments. Data are mean +/- s.e.m. g-i Fork degradation was evaluated upon HU treatment in M059K cells transfected with the indicated siRNAs for 48 h. Representative images of CldU and IdU replication tracks and scatterplots of IdU/CldU-tract length ratios for individual replication forks are shown. Fibers evaluated from more than 150 counts from three independent experiments. Data are mean +/- s.e.m. A two-sided Mann–Whitney rank-sum test was used to determine if differences were significant. For, NS: not significant: P > 0.05 Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35414100), licensed under a CC-BY license. Not internally tested by Novus Biologicals.